Therapies targeting myeloid-derived suppressor cells in the tumor microenvironment
The tumor microenvironment (TME) is the internal environment for tumor cell production and survival. Myeloid-derived suppressor cells (MDSCs) in the TME are the main immunosuppressive cells that maintain cancer progression.
MDSCs inhibit the antitumor immune response and play an important role in promoting tumor occurrence and development. Therefore, MDSCs in the TME become one of the main targets to improve the efficacy of tumor immunotherapy.
Download this mini-review to learn more about the TME and immunotherapy strategies that target MDSCs, including:
- Depletion of MDSC populations and infiltration
- Inhibition of MDSC recruitment and transport
- Anticytokine therapy targeting MDSCs
This mini-review aims to provide novel directions for cancer treatments from the perspective of targeting MDSCs in the tumor microenvironment. The immunotherapy strategies include depleting the populations and infiltration, inhibiting the recruitment and transport, and anticytokine therapy. These efforts will bring considerable opportunities for existing cancer treatments.
Explore Sino Biological’s wide range of proteins and antibodies for targets in the tumor microenvironment: Tumor Microenvironment Research Reagents (sinobiological.com)
This content was provided by Sino Biological.
Submit Your Research to the F1000Research Oncology Gateway
Share your oncology research with the global scientific community through the F1000Research Oncology Gateway. With trusted publishing, open access, and transparent peer review, your work will uphold the highest standards of research integrity while driving innovation in cancer treatment and understanding.
Join a trusted platform that accelerates progress in oncology. Submit your research today at F1000Research Oncology Gateway.
